Okta, Inc. vs Stryker Corporation — how do they compare? Okta, Inc. trades at $172.8 (market cap $30.20B), while Stryker Corporation trades at $277.44 (market cap $105.63B). The key difference: Stryker Corporation is far larger — about 3.5× Okta, Inc.'s market cap, and Stryker Corporation pays a 1.28% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| OKTA | SYK | |
|---|---|---|
Market Cap | $30.20B | $105.63B |
Sector | Technology | Technology |
52-Week High | $173.04 | $388.79 |
52-Week Low | $62.93 | $275.39 |
Enterprise Value | $27.95B | $117.10B |
Dividend Yield | — | 1.28% |
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $167.60, down 1.76% on the day but up 94% year-to-date, driven by strong earnings beats and AI-driven demand for cybersecurity. The stock is in a bullish technical trend with support at $166 and resistance at $170. Fundamentals show improving profitability, with Q2 2026 EPS of $1.05 beating estimates, revenue growth accelerating to $2.61 billion in 2025, and a net income margin turning positive to 9.63% in 2026 projections. Analyst sentiment remains overwhelmingly positive with a $181.61 consensus target.
The outlook for OKTA is bullish, supported by robust earnings momentum, AI security adoption, and strong institutional backing. Key opportunities include expanding AI-agent security offerings and sustained revenue growth. Risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and insider selling activity. The stock's proximity to its 52-week high suggests cautious entry points may be warranted despite positive catalysts.
Stryker Corporation (SYK) trades at $276.43, down 8.81% over 24 hours, reflecting bearish technical signals but strong fundamentals. The stock shows robust profitability with a 14.43% net income margin and consistent earnings beats in recent quarters. Recent developments include the launch of an FDA-cleared surgical app for Apple Vision Pro and the acquisition of ZuriMED to expand shoulder care offerings. Analyst consensus remains strongly bullish with a $372.89 price target, though ongoing securities fraud investigations pose near-term sentiment risks.
Outlook is positive long-term due to solid financial health, innovation pipeline, and institutional support, but investors face volatility from legal probes and technical bearishness. The stock's current dip may present a buying opportunity for those confident in Stryker's market position and growth trajectory, balanced against regulatory and market risks.
Trailing returns across standard periods
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →